Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene s Q2 Revenues Up 26 Percent, Earnings Grow 40 Percent

Click  here to read an updated version of this article.

NEW YORK, Aug. 10 (GenomeWeb News) - Stratagene yesterday reported increased revenues and earnings for the second quarter of 2005.


Revenues for the quarter grew 26 percent to $24.9 million from $19.7 million for the year-ago period. The company saw growth across its life science and diagnostics businesses, with quantitative PCR being the fastest growing product line in life sciences.


R&D expenses were flat at $2.9 million, compared to $2.8 million during the year-ago period.


The company's net income for the quarter was $2.1 million, or $.1 per share, up 40 percent over last year's income of $1.5 million, or $.08 per share, during the same period. Net income this quarter was positivley impacted by lower interest expenses due to a reduction in outstanding debt.


As of June 30, Stratagene had $5.7 million in cash, cash equivalents, and marketable securities.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.